Biocon profit and loss

Latest FY26

Revenue: ₹16,927cr+10.9% on FY25
EBITDA: ₹3,455cr+9.1% on FY25
Net profit: ₹369cr−74.2% on FY25
EPS: ₹2.82−66.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	17,321	16,927	15,262	14,756	11,174	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	317	343	1,208	866	376
	17,638	17,270	16,470	15,621	11,550
	5,478	5,278	4,277	5,072	3,191
	907	1,363	627	683	626
	−632	−950	294	−857	−154
	3,591	3,508	3,144	2,664	2,181
	927	990	897	974	419
	2,049	1,957	1,687	1,569	1,113
	4,441	4,273	3,754	3,895	2,818
	16,761	16,419	14,680	14,000	10,195
	3,536	3,455	3,166	3,299	2,512
	1,487	1,499	1,479	1,730	1,399
Profit
	878	851	1,790	1,621	1,356
	−399	−403	96.5	−11.6	−291
	479	448	1,887	1,609	1,064
	493	444	369	314	254
	−431	−365	87.9	−86.9	0.0
	62.2	79.1	457	227	254
	0.0	0.0	0.0	−84.2	−167
	416	369	1,429	1,298	643
	416	369	1,429	1,382	810
	3,039	2,044	437	387	76.6
	3,455	2,413	1,866	1,685	720
	495	386	1,013	1,023	463
	−78.9	−16.8	416	275	180
Per share
	₹3.40	₹2.82	₹8.46	₹8.55	₹3.88
	₹3.38	₹2.82	₹8.46	₹8.54	₹3.87
Other comprehensive income — detail
	3,039	2,044	437	—	—
	1,153	427	−14.8	13.6	−42.2
	61.0	22.3	2.6	—	—
	—	—	—	−3.0	−2.4
	1,907	1,549	407	440	88.5
	−39.2	−91.2	−47.1	—	—
	—	—	—	69.5	−27.9
	3,386	2,299	1,370	1,291	577
	69.2	114	497	393	143
Per share — as-filed variants
	₹3.40	₹2.82	₹8.46	₹8.55	₹3.88
	₹3.38	₹2.82	₹8.46	₹8.54	₹3.87
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	11,568	11,236	10,064	9,858	7,511
	66.8%	66.4%	65.9%	66.8%	67.2%
Adjusted (ex-exceptional items) — derived
	878	851	1,790	1,621	1,356
	−399	−403	96.5	−11.6	−291
	764	701	1,356	1,308	865
	₹6.24	₹5.36	₹8.03	₹8.62	₹5.22

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BIOCON₹350.70

Biocon Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA DRREDDY SYNGENE MANKIND GLENMARK LAURUSLABS ALKEM LUPINMcap ₹56,848 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	11,174.2	14,755.7	15,261.7	16,927.0	17,321.1
Other Income	375.9	865.5	1,208.2	342.5	317.3
Total Income	11,550.1	15,621.2	16,469.9	17,269.5	17,638.4
Expenses
+ Cost of Materials Consumed	3,191.1	5,071.9	4,276.7	5,277.6	5,477.7
+ Purchases of Stock-in-Trade	626.1	682.7	626.6	1,362.6	907.4
+ Changes in Inventories	-154.1	-856.7	294.2	-949.5	-631.9
+ Employee Benefit Expense	2,181.0	2,664.1	3,144.4	3,508.0	3,591.0
+ Finance Costs	419.0	974.4	897.4	990.3	926.8
+ Depreciation & Amortisation	1,113.1	1,568.8	1,687.0	1,956.7	2,049.1
+ Other Expenses	2,818.4	3,895.0	3,753.5	4,273.0	4,440.5
Total Expenses	10,194.6	14,000.2	14,679.8	16,418.7	16,760.6
EBITDA	2,511.7	3,298.7	3,166.3	3,455.3	3,536.4
EBIT	1,398.6	1,729.9	1,479.3	1,498.6	1,487.3
Profit
PBT before Exceptional Items	1,355.5	1,621.0	1,790.1	850.8	877.8
+ Exceptional Items	-291.4	-11.6	96.5	-402.9	-399.2
Pretax Income	1,064.1	1,609.4	1,886.6	447.9	478.6
+ Current Tax	254.1	314.3	369.3	443.6	492.7
+ Deferred Tax	0.0	-86.9	87.9	-364.5	-430.5
Tax Expense	254.1	227.4	457.2	79.1	62.2
+ Share of Associates & JVs	-167.0	-84.2	0.0	0.0	0.0
Net Income	643.0	1,297.8	1,429.4	368.8	416.4
+ Net Income — Continuing Ops	810.0	1,382.0	1,429.4	368.8	416.4
+ Other Comprehensive Income	76.6	386.7	436.7	2,044.3	3,038.6
Total Comprehensive Income	719.6	1,684.5	1,866.1	2,413.1	3,455.0
Net Income to Common	462.7	1,022.5	1,013.3	385.6	495.3
Minority Interest	180.3	275.3	416.1	-16.8	-78.9
Per Share
Basic EPS	3.88	8.55	8.46	2.82	3.40
Diluted EPS	3.87	8.54	8.46	2.82	3.38
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	436.7	2,044.3	3,038.6
+ Items NOT to be Reclassified to P&L	-42.2	13.6	-14.8	426.7	1,153.0
+ Tax on Items NOT to be Reclassified	—	—	2.6	22.3	61.0
+ Tax on Items NOT to be Reclassified — alt tag	-2.4	-3.0	—	—	—
+ Items to be Reclassified to P&L	88.5	439.6	407.0	1,548.7	1,907.4
+ Tax on Items to be Reclassified	—	—	-47.1	-91.2	-39.2
+ Tax on Items to be Reclassified — alt tag	-27.9	69.5	—	—	—
Comprehensive Income — Owners of Parent	576.5	1,291.3	1,369.6	2,299.3	3,385.8
Comprehensive Income — Non-controlling Interests	143.1	393.2	496.5	113.8	69.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.88	8.55	8.46	2.82	3.40
Diluted EPS — Continuing Operations	3.87	8.54	8.46	2.82	3.38
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	7,511.1	9,857.8	10,064.2	11,236.3	11,567.9
Gross Margin %	67.22	66.81	65.94	66.38	66.79
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,355.5	1,621.0	1,790.1	850.8	877.8
− Exceptional Items (reconciliation)	-291.4	-11.6	96.5	-402.9	-399.2
Net Income Adj (tax-effected)	864.8	1,307.8	1,356.3	700.5	763.7
EPS Adj	5.22	8.62	8.03	5.36	6.24
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	600.3	600.3	600.3	810.5	814.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.